Suppr超能文献

慢性粒单核细胞白血病患者肾功能降低的意义。

Significance of reduced renal function in patients with chronic myelomonocytic leukemia.

机构信息

Medical School, Sigmund Freud University, Vienna, Austria.

Department of Internal Medicine V with Hematology, Oncology and Palliative Care, Hospital Hietzing, Wolkersbergenstraße 1, 1130, Vienna, Austria.

出版信息

Wien Med Wochenschr. 2023 Feb;173(1-2):3-8. doi: 10.1007/s10354-022-00977-4. Epub 2022 Oct 25.

Abstract

In a retrospective study, we analyzed the prevalence of increased creatinine levels in 166 patients with chronic myelomonocytic leukemia (CMML), their potential prognostic impact, and potential correlations with laboratory and molecular features. Increased creatinine values (> 1.1 mg/dl) were found in 71 of 166 (43%) patients. The median survival of patients with increased creatinine values was significantly shorter than in patients without impairment of renal function (20 vs. 52 months, p < 0.001). Patients with increased creatinine values were older, were more often male, had higher leukocyte counts, higher monocyte counts, and higher lactatdehydrogenase (LDH) values. There was a trend toward a higher prevalence of CBL and ASXL1 mutations in patients with renal impairment. Our findings show a high prevalence of renal abnormalities in patients with CMML. Increased creatinine values were identified as a new prognostic marker. These findings may be important for the individualized management of this heterogenous group of patients.

摘要

在一项回顾性研究中,我们分析了 166 例慢性髓单核细胞白血病(CMML)患者中肌酐水平升高的发生率、其潜在的预后影响以及与实验室和分子特征的潜在相关性。在 166 例患者中,有 71 例(43%)患者肌酐值升高。与肾功能未受损的患者相比,肌酐值升高的患者中位生存期明显缩短(20 个月 vs. 52 个月,p < 0.001)。肌酐值升高的患者年龄较大,男性较多,白细胞计数、单核细胞计数和乳酸脱氢酶(LDH)值较高。肾功能不全患者中 CBL 和 ASXL1 突变的发生率呈上升趋势。我们的研究结果显示 CMML 患者存在较高的肾脏异常发生率。肌酐值升高被确定为新的预后标志物。这些发现对于该异质性患者群体的个体化治疗可能很重要。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6544/9876845/5f1e4b4092fd/10354_2022_977_Fig1_HTML.jpg

相似文献

1
Significance of reduced renal function in patients with chronic myelomonocytic leukemia.
Wien Med Wochenschr. 2023 Feb;173(1-2):3-8. doi: 10.1007/s10354-022-00977-4. Epub 2022 Oct 25.
2
3
Significance of hypergammaglobulinemia in patients with chronic myelomonocytic leukemia.
Wien Med Wochenschr. 2023 Feb;173(1-2):21-26. doi: 10.1007/s10354-022-00983-6. Epub 2022 Nov 29.
4
Significance of abnormal blood coagulation in patients with chronic myelomonocytic leukemia.
Wien Med Wochenschr. 2023 Feb;173(1-2):9-14. doi: 10.1007/s10354-022-00969-4. Epub 2022 Oct 7.
5
[Clinical Characteristics and Survival Analysis of Patients with Chronic Myelomonocytic Leukemia].
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2023 Apr;31(2):476-482. doi: 10.19746/j.cnki.issn.1009-2137.2023.02.024.
6
Significance of cardiovascular comorbidity in patients with chronic myelomonocytic leukemia.
Wien Med Wochenschr. 2023 Feb;173(1-2):27-33. doi: 10.1007/s10354-022-00982-7. Epub 2022 Nov 21.
7
Prognostic score including gene mutations in chronic myelomonocytic leukemia.
J Clin Oncol. 2013 Jul 1;31(19):2428-36. doi: 10.1200/JCO.2012.47.3314. Epub 2013 May 20.
8
RAS mutations contribute to evolution of chronic myelomonocytic leukemia to the proliferative variant.
Clin Cancer Res. 2010 Apr 15;16(8):2246-56. doi: 10.1158/1078-0432.CCR-09-2112. Epub 2010 Apr 6.
10
Age-related mutations and chronic myelomonocytic leukemia.
Leukemia. 2016 Apr;30(4):906-13. doi: 10.1038/leu.2015.337. Epub 2015 Dec 9.

引用本文的文献

1
Kidney and Urinary Tract Involvement in Chronic Myelomonocytic Leukemia.
Kidney Med. 2023 Dec 5;6(2):100769. doi: 10.1016/j.xkme.2023.100769. eCollection 2024 Feb.

本文引用的文献

2
Impact of age on the cumulative risk of transformation in patients with chronic myelomonocytic leukaemia.
Eur J Haematol. 2021 Aug;107(2):265-274. doi: 10.1111/ejh.13647. Epub 2021 Jun 1.
3
Kidney Involvement in Patients With Chronic Myelomonocytic Leukemia or BCR-ABL-Negative Myeloproliferative Neoplasms.
Kidney Int Rep. 2020 Dec 14;6(3):737-745. doi: 10.1016/j.ekir.2020.12.005. eCollection 2021 Mar.
4
A rare cause of acute kidney injury with chronic myelomonocytic leukemia.
CEN Case Rep. 2021 Aug;10(3):320-325. doi: 10.1007/s13730-020-00567-6. Epub 2021 Jan 6.
5
Renal disease associated with myeloproliferative neoplasms and myelodysplastic syndrome/myeloproliferative neoplasms.
Histopathology. 2021 Apr;78(5):738-748. doi: 10.1111/his.14282. Epub 2020 Dec 14.
6
Reduced renal function strongly affects survival and thrombosis in patients with myelofibrosis.
Ann Hematol. 2020 Dec;99(12):2779-2785. doi: 10.1007/s00277-020-04239-4. Epub 2020 Aug 29.
10
Real-world Data for Clinical Evidence Generation in Oncology.
J Natl Cancer Inst. 2017 Nov 1;109(11). doi: 10.1093/jnci/djx187.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验